A panel of researchers developed evidence-based guidelines to support clinical decision making regarding transfusion support for patients with sickle cell disease.
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Treatment regimens including immunomodulatory agents or proteasome inhibitors could lead to development of peripheral neuropathy.
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Several factors need to be considered when choosing optimal therapy for older patients with hematologic malignancies, particularly when it comes to managing toxicity.